Source: European Journal of Pharmacology. Unidade: FMRP
Subjects: CARDIOPATIAS, INSUFICIÊNCIA CARDÍACA, ANTINEOPLÁSICOS, NEOPLASIAS
ABNT
CAMPOS, Erica C. et al. Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. European Journal of Pharmacology, v. 670, n. 2/3, p. 541-553, 2011Tradução . . Disponível em: https://doi.org/10.1016/j.ejphar.2011.09.021. Acesso em: 01 jun. 2024.APA
Campos, E. C., O'Connell, J. L., Malvestio, L. M., Romano, M. M. D., Ramos, S. G., Celes, M. R. N., et al. (2011). Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. European Journal of Pharmacology, 670( 2/3), 541-553. doi:10.1016/j.ejphar.2011.09.021NLM
Campos EC, O'Connell JL, Malvestio LM, Romano MMD, Ramos SG, Celes MRN, Prado CM, Simões MV, Rossi MA. Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy [Internet]. European Journal of Pharmacology. 2011 ; 670( 2/3): 541-553.[citado 2024 jun. 01 ] Available from: https://doi.org/10.1016/j.ejphar.2011.09.021Vancouver
Campos EC, O'Connell JL, Malvestio LM, Romano MMD, Ramos SG, Celes MRN, Prado CM, Simões MV, Rossi MA. Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy [Internet]. European Journal of Pharmacology. 2011 ; 670( 2/3): 541-553.[citado 2024 jun. 01 ] Available from: https://doi.org/10.1016/j.ejphar.2011.09.021